Survey tool (does not include introductory email)

1. What state do you currently practice/work in?
2. About how many Hepatitis C teleECHO sessions have you attended?
   1. Less than 3
   2. 3-10
   3. More than 10
3. How did you hear about how to participate in teleECHO? (select one)
   1. In-person training
   2. Email from Area/Health Board
   3. Colleague in same health facility
   4. Other (please specify)
4. Which ECHO have you participated in? (select all that apply).
   1. University of New Mexico
   2. Northwest Portland Area Indian Health Board
   3. Cherokee
   4. Other (please specify)
5. Does your clinic treat HCV? (select one)
   1. Yes, before it ever participated in ECHO
   2. Yes, subsequent to participating in ECHO
   3. Not yet
   4. Not Applicable
6. How much of a BARRIER is the "time it takes to access drugs/cost of drugs" to treating patients with HCV (or treating more patients)?

0-Not a barrier

1-minimal

2-moderate

3-Extensive barrier

1. How much of a BARRIER is the "need for more frequent/regular specialist guidance" to treating patients with HCV (or treating more patients)?

0-Not a barrier

1-minimal

2-moderate

3-Extensive barrier

1. How much of a BARRIER is "getting patients into care/follow-up" to treating patients with HCV (or treating more patients)?

0-Not a barrier

1-minimal

2-moderate

3-Extensive barrier

1. How much of a BARRIER is "limited clinical time that can be devoted to HCV services" to treating patients with HCV (or treating more patients)?

0-Not a barrier

1-minimal

2-moderate

3-Extensive barrier

1. How USEFUL do you find "presenting cases" as part of the teleECHO session?

0-Not useful

1-Minimal

2-Moderate

3-Extremely useful

1. How USEFUL do you find "listening to case presentations" as part of the teleECHO session?

0-Not useful

1-Minimal

2-Moderate

3-Extremely useful

1. How USEFUL do you find the "didactic/teaching presentation" as part of the teleECHO session?

0-Not useful

1-Minimal

2-Moderate

3-Extremely useful

1. How USEFUL do you find the "program information (e.g. sharing strategies to obtain HCV drugs)" as part of the teleECHO session?

0-Not useful

1-Minimal

2-Moderate

3-Extremely useful

1. {if participant rated usefulness as “not useful” or “minimal”}If you answered "0" or "1" please comment on how these areas (e.g. didactic/case presentation, etc) could be more useful?
2. What area do you think teleECHO would be most useful to you to improve? (select one)
   1. Clinical/treatment plans
   2. Drug interactions
   3. Substance use disorders
   4. More complex case presentation
   5. Less complex case presenatation
   6. More relevant didactic/teaching presentations
   7. Technical issues with video/sound quality
   8. Other (please specify)
3. About what percentage of the patients with hepatitis C who you treat do you present to teleECHO?
   1. All
   2. Most
   3. About half
   4. Less than half
   5. Not applicable
4. How useful is the CME option offered by the Hepatitis C teleECHO?
   1. Highly
   2. Somewhat
   3. Not Very
   4. Didn't know about it
5. {if participant rated CME option as “not very” useful} What would you say is the reason CMEs are not that useful?
   1. I prefer to get them elsewhere
   2. It is a bit of a hassle via teleECHO links online
   3. Other (please specify)
6. Do you have additional comments or suggestions about how the hepatitis C teleECHO services can be improved to suit you and/or your facility?
7. May we contact you if we have further questions?
   1. YES
   2. NO

* Great, please reply with your email address and phone number
* Great, thank you for your feedback and time.